Gabelli Funds LLC Cuts Position in DaVita Inc. (NYSE:DVA)

Gabelli Funds LLC decreased its holdings in DaVita Inc. (NYSE:DVA) by 11.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 82,500 shares of the company’s stock after selling 10,500 shares during the period. Gabelli Funds LLC’s holdings in DaVita were worth $8,289,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of DVA. Raymond James & Associates grew its position in DaVita by 4.0% in the first quarter. Raymond James & Associates now owns 22,651 shares of the company’s stock valued at $2,562,000 after acquiring an additional 865 shares in the last quarter. American Century Companies Inc. grew its position in DaVita by 37.4% in the first quarter. American Century Companies Inc. now owns 6,555 shares of the company’s stock valued at $741,000 after acquiring an additional 1,785 shares in the last quarter. US Bancorp DE grew its position in DaVita by 63.6% in the first quarter. US Bancorp DE now owns 2,998 shares of the company’s stock valued at $338,000 after acquiring an additional 1,166 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in DaVita by 7.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 3,551 shares of the company’s stock valued at $402,000 after acquiring an additional 242 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in DaVita by 847.8% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,090 shares of the company’s stock valued at $123,000 after acquiring an additional 975 shares in the last quarter. Hedge funds and other institutional investors own 84.69% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the subject of several recent research reports. Truist Financial lowered their price objective on shares of DaVita from $115.00 to $104.00 and set a “hold” rating for the company in a research report on Wednesday, October 11th. UBS Group decreased their price target on shares of DaVita from $142.00 to $113.00 and set a “buy” rating for the company in a research report on Friday. StockNews.com started coverage on shares of DaVita in a research report on Thursday, October 5th. They set a “buy” rating for the company. Finally, TheStreet downgraded shares of DaVita from a “b-” rating to a “c” rating in a research report on Monday, October 23rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $102.67.

DaVita Stock Up 1.4 %

DVA stock opened at $97.53 on Tuesday. The firm has a 50 day simple moving average of $87.84 and a 200-day simple moving average of $95.93. DaVita Inc. has a twelve month low of $69.55 and a twelve month high of $116.97. The company has a market capitalization of $8.90 billion, a P/E ratio of 14.96, a PEG ratio of 0.63 and a beta of 0.98. The company has a current ratio of 1.24, a quick ratio of 1.19 and a debt-to-equity ratio of 6.01.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $2.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.93. DaVita had a return on equity of 63.38% and a net margin of 5.11%. The firm had revenue of $3.12 billion for the quarter, compared to analysts’ expectations of $3.02 billion. During the same period last year, the business posted $1.45 earnings per share. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. On average, equities research analysts predict that DaVita Inc. will post 8.17 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.